A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-26 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
==== London Bullion Market Association ==== In November 2020, the London Bullion Market Association wrote a letter to a number of countries with huge gold markets, including Dubai (United Arab Emirates), China, Singapore, South Africa, Russia, Japan, United States and others, laying out the standards regarding money laundering and other issues like where they sourced their gold. It also threatened that these countries could be blacklisted, if they failed to meet the regulatory standards. This was LBMA's first move to challenge the illegal or unethical production and trading of gold.
X-linked chronic granulomatous disease (CGD) autosomal recessive cytochrome b-negative CGD autosomal recessive cytochrome b-positive CGD type I autosomal recessive cytochrome b-positive CGD type II atypical granulomatous disease
No. (number) column A running positive integer for reference, equal to the position in the tables. This number may change in the future, especially for nuclides with short lives, as better half-life estimates become available.
Sources: en.wikipedia.org
==== Economic gains ==== In 2014, the aquaculture produced fish overtook wild caught fish, in supply for human food. This means there is a huge demand for vaccines, in prevention of diseases. The reported annual loss fish, calculates to >10 billion USD. This is from approximately 10% of all fishes dying from infectious diseases. The high annual losses increases the demand for vaccines. Even though there are about 24 traditionally used vaccines, there is still demand for more vaccines. The breakthrough of DNA-vaccines has sunk the cost of vaccines. The alternative to vaccines would be antibiotics and chemotherapy, which are more expensive and with bigger drawbacks. DNA-vaccines have become the most cost-efficient method of preventing infectious diseases. This bodes well for DNA-vaccines becoming the new standard both in fish vaccines, and in general vaccines.
Seeing an opportunity in Napoleon I's historic defeat, Prussia, Sweden and several other German states switched sides, joining Russia, the United Kingdom and others opposing Napoleon. Napoleon vowed that he would create a new army as large as the one he had sent into Russia, and quickly built up his forces in the east from 30,000 to 130,000 and eventually to 400,000. Napoleon inflicted 40,000 casualties on the Allies at Lützen (2 May 1813) and Bautzen (20–21 May 1813). Both battles involved forces of over 250,000, making them some of the largest conflicts of the wars so far. Klemens von Metternich in November 1813 offered Napoleon the Frankfurt proposals. They would allow Napoleon to remain Emperor but France would be reduced to its "natural frontiers" and lose control of most of Italy and Germany and the Netherlands. Napoleon still expected to win the wars, and rejected the terms. By 1814, as the Allies were closing in on Paris, Napoleon I did agree to the Frankfurt proposals, but it was too late and he rejected the new harsher terms proposed by the Allies.
Many mushroom species produce secondary metabolites that can be toxic, mind-altering, antibiotic, antiviral, or bioluminescent. Although there are only a small number of deadly species, several others can cause particularly severe and unpleasant symptoms. Toxicity likely plays a role in protecting the function of the basidiocarp: the mycelium has expended considerable energy and protoplasmic material to develop a structure to efficiently distribute its spores. One defense against consumption and premature destruction is the evolution of chemicals that render the mushroom inedible, either causing the consumer to vomit the meal (see emetics), or to learn to avoid consumption altogether. In addition, due to the propensity of mushrooms to absorb heavy metals, including those that are radioactive, as late as 2008, European mushrooms may have included toxicity from the 1986 Chernobyl disaster and have continued to be studied.
Sources: en.wikipedia.org
==== Other actions ==== Bromantane has been found to increase the expression of neurotrophins including brain-derived neurotrophic factor and nerve growth factor in certain rat brain areas. Although not relevant at clinical dosages, bromantane has been found to produce anticholinergic effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals, and these effects are responsible for its toxicity (that is, LD50) in animals.
Chloral hydrate is a geminal diol with the formula Cl3C−CH(OH)2. It was first used as a sedative and hypnotic in Germany in the 1870s. Over time it was replaced by safer and more effective alternatives but it remained in use in the United States until at least the 1970s. It sometimes finds usage as a laboratory chemical reagent and precursor. It is derived from chloral (trichloroacetaldehyde) by the addition of one equivalent of water.
=== Doug Rattmann === Doug Rattmann, often referred to as the "Ratman" is a character in both Portal and Portal 2. He was a former scientist working at Aperture and one of the few who survived when GLaDOS flooded the facility with neurotoxin. In the two games there are various "Ratman dens", where Doug Rattmann has left scribblings and paintings on walls in hidden rooms. Ratman's full appearance is only seen in the Portal 2: Lab Rat webcomic released by Valve prior to Portal 2's release to tie the story of the two games together. Ratman is the comic's main character. Prior to GLaDOS' rampancy and the neurotoxin release, Doug Rattmann was once an Aperture scientist. Already skeptical of the computer, the man fled from the gas and kept himself hidden from GLaDOS' view, slowly becoming more insane over an unknown stretch of time. Among the wall scribblings in the Portal dens is the sentence "The cake is a lie", which became an internet meme. The Lab Rat comic reveals that, despite his madness, Doug Rattmann identified Chell as a rejected test subject due to her high tenacity, and moved her to the top of the queue for testing. During events in Portal, he worked behind the scenes to scribble messages and warnings to Chell on the walls, leading her out of the testing chambers and towards GLaDOS. After watching her defeat the computer, he managed to escape the facility, but returned to assure Chell would be put in indefinite cryogenic storage animation after she was dragged back inside, suffering a serious injury (a shot in the leg from a turret) to complete this.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.